drugset / Trial / NCT00626782
Lucentis Versus Mitomycin C During Glaucoma Surgery
RandomizedParallel-groupOpen-labelTreatment
Summary
Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known complications of mytomycin C which include late bleb leaks, hypotony and infection.
Timeline
- Start
- 2008-01
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mitomycin (MMC) | Unknown | 0.4 mg/ml | — |
| Subject | Ranibizumab | Monoclonal antibody | 0.05 ml | Other |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Other |